Sign in

    Lin Zhang

    Research Analyst at CITIC Securities Company Limited

    Lin Zhang is an analyst at CITIC Securities Company Limited, specializing in coverage of pharmaceutical and biopharmaceutical companies. He regularly provides investment research on firms such as HUTCHMED and has established a reputation for detailed sector analysis, although specific performance metrics and rankings remain undisclosed. Zhang has developed his expertise through his ongoing tenure at CITIC Securities, and there is no publicly available information indicating previous roles or professional credentials such as FINRA registration or securities licenses.

    Lin Zhang's questions to Yatsen Holding (YSG) leadership

    Lin Zhang's questions to Yatsen Holding (YSG) leadership • Q2 2025

    Question

    Lin Zhang from CITIC Securities asked about the primary drivers for the rapid growth of skincare brands Calanique and Dr. Wu in the first half of the year and the outlook for the business. She also questioned which aspects the company would focus on to continuously improve profitability.

    Answer

    Irene Lyu, Head of M&A, Strategy & Capital Markets, attributed the skincare growth to sustained R&D investment and a strong new product pipeline, such as the VA serum and MicroMask series. She indicated the Q3 guidance reflects this positive trend. For profitability, she mentioned optimizing channel mix and streamlining expenses, expecting gradual improvement. CFO & Director Donghao Yang added that profitability will be enhanced by driving premiumization, improving marketing ROI, increasing supply chain efficiency, and gaining operating leverage from top-line growth.

    Ask Fintool Equity Research AI

    Lin Zhang's questions to Yatsen Holding (YSG) leadership • Q2 2025

    Question

    Lin Zhang from CITIC Securities asked about the primary drivers for the rapid growth of skincare brands like Calanique and Doctor Wu in the first half of the year, the outlook for the skincare business, and the specific levers the company will use to improve profitability.

    Answer

    Irene Lu, VP of Strategic Investment, attributed skincare growth to sustained R&D investment and a strong new product pipeline, citing the success of Glymit's VA serum and MicroMask series and Doctor Wu's new acid toner. CFO Dong Hao Yang added that profitability will be improved by optimizing the product mix toward premium items, enhancing marketing ROI through data-driven CRM, improving supply chain efficiency, and gaining operating leverage from continued top-line growth.

    Ask Fintool Equity Research AI

    Lin Zhang's questions to Yatsen Holding (YSG) leadership • Q2 2025

    Question

    Lin Zhang from CITIC Securities asked about the primary drivers for the rapid growth of skincare brands like Galénic and Dr. Wu in H1, the business outlook for skincare in H2 and beyond, and the specific areas where the company will focus to enhance overall profitability.

    Answer

    Irene Lyu, Head of M&A, Strategy & Capital Markets, attributed the skincare growth to sustained R&D investment and a strong new product pipeline, including Galénic's VA serum and Dr. Wu's acid toner. She noted that profitability improvements will be gradual due to continued brand investment. CFO & Director Donghao Yang added that profitability will be improved by optimizing the product mix toward premium items, enhancing marketing ROI, increasing supply chain efficiency, and gaining operating leverage from revenue growth.

    Ask Fintool Equity Research AI